GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients for six months at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.